Cargando…
Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy
BACKGROUND: Acute myeloid leukemia (AML) is a hematopoietic malignancy with a prognosis that varies with genetic heterogeneity of hematopoietic stem/progenitor cells (HSPCs). Induction chemotherapy with cytarabine and anthracycline has been the standard care for newly diagnosed AML, but about 30% of...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828578/ https://www.ncbi.nlm.nih.gov/pubmed/36197314 http://dx.doi.org/10.1002/cncr.34481 |
_version_ | 1784867305359933440 |
---|---|
author | Jia, Ruinan Ji, Min Li, Guosheng Xia, Yuan Guo, Shouhui Li, Peng Sun, Yanping Lu, Fei Zhang, Jingru Zang, Shaolei Yan, Shuxin Ye, Jingjing Xue, Fuzhong Ma, Daoxin Sun, Tao Ji, Chunyan |
author_facet | Jia, Ruinan Ji, Min Li, Guosheng Xia, Yuan Guo, Shouhui Li, Peng Sun, Yanping Lu, Fei Zhang, Jingru Zang, Shaolei Yan, Shuxin Ye, Jingjing Xue, Fuzhong Ma, Daoxin Sun, Tao Ji, Chunyan |
author_sort | Jia, Ruinan |
collection | PubMed |
description | BACKGROUND: Acute myeloid leukemia (AML) is a hematopoietic malignancy with a prognosis that varies with genetic heterogeneity of hematopoietic stem/progenitor cells (HSPCs). Induction chemotherapy with cytarabine and anthracycline has been the standard care for newly diagnosed AML, but about 30% of patients have no response to this regimen. The resistance mechanisms require deeper understanding. METHODS: In our study, using single‐cell RNA sequencing, we analyzed the heterogeneity of bone marrow CD34(+) cells from newly diagnosed patients with AML who were then divided into sensitive and resistant groups according to their responses to induction chemotherapy with cytarabine and anthracycline. We verified our findings by TCGA database, GEO datasets, and multiparameter flow cytometry. RESULTS: We established a landscape for AML CD34(+) cells and identified HSPC types based on the lineage signature genes. Interestingly, we found a cell population with CRIP1 ( high ) LGALS1 ( high ) S100As( high ) showing features of granulocyte‐monocyte progenitors was associated with poor prognosis of AML. And two cell populations marked by CD34(+)CD52(+) or CD34(+)CD74(+)DAP12(+) were related to good response to induction therapy, showing characteristics of hematopoietic stem cells. CONCLUSION: Our study indicates the subclones of CD34(+) cells confers for outcomes of AML and provides biomarkers to predict the response of patients with AML to induction chemotherapy. |
format | Online Article Text |
id | pubmed-9828578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98285782023-01-10 Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy Jia, Ruinan Ji, Min Li, Guosheng Xia, Yuan Guo, Shouhui Li, Peng Sun, Yanping Lu, Fei Zhang, Jingru Zang, Shaolei Yan, Shuxin Ye, Jingjing Xue, Fuzhong Ma, Daoxin Sun, Tao Ji, Chunyan Cancer Original Articles BACKGROUND: Acute myeloid leukemia (AML) is a hematopoietic malignancy with a prognosis that varies with genetic heterogeneity of hematopoietic stem/progenitor cells (HSPCs). Induction chemotherapy with cytarabine and anthracycline has been the standard care for newly diagnosed AML, but about 30% of patients have no response to this regimen. The resistance mechanisms require deeper understanding. METHODS: In our study, using single‐cell RNA sequencing, we analyzed the heterogeneity of bone marrow CD34(+) cells from newly diagnosed patients with AML who were then divided into sensitive and resistant groups according to their responses to induction chemotherapy with cytarabine and anthracycline. We verified our findings by TCGA database, GEO datasets, and multiparameter flow cytometry. RESULTS: We established a landscape for AML CD34(+) cells and identified HSPC types based on the lineage signature genes. Interestingly, we found a cell population with CRIP1 ( high ) LGALS1 ( high ) S100As( high ) showing features of granulocyte‐monocyte progenitors was associated with poor prognosis of AML. And two cell populations marked by CD34(+)CD52(+) or CD34(+)CD74(+)DAP12(+) were related to good response to induction therapy, showing characteristics of hematopoietic stem cells. CONCLUSION: Our study indicates the subclones of CD34(+) cells confers for outcomes of AML and provides biomarkers to predict the response of patients with AML to induction chemotherapy. John Wiley and Sons Inc. 2022-10-05 2022-11-15 /pmc/articles/PMC9828578/ /pubmed/36197314 http://dx.doi.org/10.1002/cncr.34481 Text en © 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Jia, Ruinan Ji, Min Li, Guosheng Xia, Yuan Guo, Shouhui Li, Peng Sun, Yanping Lu, Fei Zhang, Jingru Zang, Shaolei Yan, Shuxin Ye, Jingjing Xue, Fuzhong Ma, Daoxin Sun, Tao Ji, Chunyan Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy |
title | Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy |
title_full | Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy |
title_fullStr | Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy |
title_full_unstemmed | Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy |
title_short | Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy |
title_sort | subclones of bone marrow cd34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828578/ https://www.ncbi.nlm.nih.gov/pubmed/36197314 http://dx.doi.org/10.1002/cncr.34481 |
work_keys_str_mv | AT jiaruinan subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT jimin subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT liguosheng subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT xiayuan subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT guoshouhui subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT lipeng subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT sunyanping subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT lufei subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT zhangjingru subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT zangshaolei subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT yanshuxin subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT yejingjing subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT xuefuzhong subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT madaoxin subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT suntao subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy AT jichunyan subclonesofbonemarrowcd34cellsinacutemyeloidleukemiaatdiagnosisconferresponsesofpatientstoinductionchemotherapy |